Drug class
Peptide hormone; calcitonin receptor agonist and inhibitor of osteoclastic bone resorption
Mechanism of action
Binds calcitonin receptors on osteoclasts, reducing osteoclast activity and bone resorption. It also has effects on renal calcium and phosphate handling; clinical use depends on formulation and jurisdiction.
General use cases
- Short-term treatment of hypercalcaemia when other measures are inadequate
- Treatment of Paget disease of bone in selected patients when alternative therapies are unsuitable
- Selected osteoporosis indications in some jurisdictions; long-term use is restricted or discouraged in certain products because of safety concerns
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
